Company intelligence / Profile preview
PepKon
Paris, Ile de France, Francepepkon.fr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
PepKon is a French biotech company developing first-in-class peptide therapeutics for oncology. Its lead candidate targets the TSP-1/CD47 pathway, aiming to address refractory and incurable cancers. The company leverages a proprietary AI-driven platform for peptide design and optimization. As of 2025, its programs are in preclinical development with ambitions to advance into first-in-human clinical trials.[1][3][4][5]
- Therapeutic areas
- Oncology
- Modalities
- Peptides[1][3][4][5]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with top-tier international institutions in cancer research[1]
Beyond the preview
Go deeper on PepKon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PepKon.